(Reuters) - Cambridge, Massachusetts-based Biogen said the drug, lixivaptan, is an oral compound expected to enter a late-stage, or Phase III, clinical trial this year in heart patients with hyponatremia, a condition that occurs when the level of sodium in the blood is too low.
Biogen will pay Philadelphia-based Cardiokine $50 million up front and would make up to $170 million in additional payments if and when certain development milestones were met, as well as royalties on sales.
Read more at Reuters.com Mergers News
Biogen will pay Philadelphia-based Cardiokine $50 million up front and would make up to $170 million in additional payments if and when certain development milestones were met, as well as royalties on sales.
Read more at Reuters.com Mergers News
No comments:
Post a Comment